Book Section

© 2017 Elsevier Inc. All rights reserved. Angiogenesis is a complex multifaceted process essential for cancer growth and progression. The underlying biology regulating angiogenesis is incredibly complicated, involving interaction between cancer cells and the tumor microenvironment. Angiogenic growth factor and receptor targets have been exploited to develop antiangiogenic therapies that have been successfully translated into clinical trials. Adoption of these agents into the clinical arena has improved survival in women with selected gynecologic cancers. The incorporation of bevacizumab, the most studied antiangiogenic, has received regulatory approval for the treatment of ovarian and cervical cancers. Further research has elucidated novel biomarkers and targets currently in preclinical and early clinical trial development. Translational research from pivotal trials has identified predictive biomarkers that can be explored in integral biomarker-directed trials. If successful, biomarkers to direct antiangiogenic therapy will identify women most likely to benefit from treatment and avoid unnecessary toxicity and cost.

Full Text

Duke Authors

Cited Authors

  • Secord, AA; Siamakpour-Reihani, S

Published Date

  • February 22, 2017

Book Title

  • Translational Advances in Gynecologic Cancers

Start / End Page

  • 79 - 109

International Standard Book Number 13 (ISBN-13)

  • 9780128037416

Digital Object Identifier (DOI)

  • 10.1016/B978-0-12-803741-6.00005-7

Citation Source

  • Scopus